crizotinib
Novartis’ Zykadia more effective than chemo, new study shows
October 13, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alcensa, Novartis, Roche, Xalkori, ceritinib, crizotinib, lung cancer, zykadia
Phase III results for Novartis’ cancer drug Zykadia (ceritinib) have revealed it as more effective than chemo at halting progression …
Roche’s Alecensa receives second FDA Breakthrough Therapy Designation
October 4, 2016Manufacturing and Production ALK+, Alecensa, FDA, Roche, alk, crizotinib
Alecensa has been designated as a breakthrough therapy, which will speed up the process towards FDA approval, should clinical trials …
Pfizer’s Xalkori price drop secures NICE recommendation
August 18, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, Pfizer, Xalkori, crizotinib, lung cancer
The National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Xalkori (crizotinib) as a treatment for lung cancer, …
Pfizer lung cancer treatment gets expanded EU approval
December 1, 2015Research and Development, Sales and Marketing NSCLC, Pfizer, Xalkori, crizotinib, lung cancer, non-small cell lung cancer
Pfizer UK has received European Commission approval for a label update to expand use of Xalkori (crizotinib) to first-line treatment …
FDA approves Pfizer’s lung cancer drug Xalkori
August 30, 2011Sales and Marketing FDA, Pfizer, Xalkori, crizotinib
Pfizer’s lung cancer drug Xalkori has been approved by the FDA, a month ahead of schedule. Xalkori (crizotinib) is now …
EMA to review two new Pfizer cancer drugs
August 19, 2011Sales and Marketing Cancer, Pfizer, bosutinib, crizotinib
The EMA has accepted Pfizer’s regulatory submissions for two of its new cancer compounds. The first is its much-lauded crizotinib, …
Pfizer files lung cancer drug in US and Japan
May 18, 2011Sales and Marketing NSCLC, Pfizer, crizotinib
Pfizer has submitted its oral lung cancer drug crizotinib for regulatory approval in the US and Japan. Crizotinib is an …
No magic bullet, but a growing arsenal against lung cancer
February 23, 2011Research and Development ASA404, Cancer, Iressa, NSCLC, Tarceva, afatinib, crizotinib, figitumumab, lung cancer, non small cell lung cancer, non-small cell lung cancer
A man in his 70s is waiting for his appointment with the oncologist after being referred there by his family …
AZ and Pfizer support personalised medicine database
February 8, 2011Research and Development AZ, AstraZeneca, Cancer Research UK, Iressa, Pfizer, crizotinib, gefitinib, personalised medicine
AstraZeneca and Pfizer have teamed up with leading charity Cancer Research UK to help develop its stratified medicines programme. Stratified …
Key drug launches for 2011
January 20, 2011Sales and Marketing Benlysta, Cladribine, Movectro, Pradaxa, Xarelto, axitinib, boceprevir, crizotinib, telaprevir
This year is expected to see new treatments for hepatitis C, multiple sclerosis and lupus among those that could reach …
Pfizer lung cancer drug gets ‘rolling’ fast-track status in US
January 13, 2011Sales and Marketing Cancer, NSCLC, axitinib, bosutinib, crizotinib, non-small cell lung cancer
Pfizer has initiated a ‘rolling’ submission for its new oral ALK lung cancer drug crizotinib that could see it on …
Pfizer to seek US approval for crizotinib next year
November 1, 2010Research and Development, Sales and Marketing FDA submission, NSCLC, Pfizer, crizotinib, lung cancer, non-small cell lung cancer
Pfizer will submit its lung cancer candidate crizotinib to the FDA for US approval in the first half of next …
‘Stellar’ performance from targeted lung cancer drug
June 9, 2010Research and Development Pfizer, biomarkers, crizotinib
A new targeted treatment for non small cell lung cancer has produced spectacular results in a sub-group of patients. Pfizer’s …
